October 03, 2011
Torys, with a team led by partner Cheryl Reicin, acted as counsel to the agents in a private placement component of Trimel Phar going public transaction. Below is an excerpt of Lexpert’s description of the transaction, which was included in the publication’s “Big Deals” section.
On July 14, 2011, Trimel Pharmaceuticals Corporation (Trimel) completed a going public transaction valued at approximately $200 million consisting of a private placement of securities of its Barbados subsidiary, Trimel BioPharma Holdings Inc. (“Trimel Holdings”), an amalgamation, reverse takeover and listing on the Toronto Stock Exchange and the clearance of a non-offering prospectus with the Ontario Securities Commission. The reverse takeover constituted the qualifying transaction for J5 Acquisition Corp. (J5), Trimel’s predecessor, pursuant to Policy 2.4 – Capital Pool Companies of the TSX Venture Exchange. The net proceeds of the private placement will be used by Trimel to further develop its 21st century dosing technologies specifically designed to avoid first-pass metabolism, including Trimel's lead product candidate, Compleo TRT, indicated for the treatment of male hypogonadism or low testosterone —commonly known as “Low T.” Trimel’s shares trade on the Toronto Stock Exchange under the symbol TRL.
The private placement component of the transaction was completed through a syndicate of agents led by GMP Securities L.P. and Cannaccord Genuity Corp.
. . .Torys LLP acted as counsel to the agents, with a team comprising Cheryl Reicin, Thomas Yeo, Andrew Prodanyk, Alison Harnick and Eli Monas (corporate and securities) and Ingrid VanderElst, Karen Townsend and Sumeet Dang (intellectual property).
For Lexpert’s full description of the deal, click here.